Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $92 from $88 and keeps an Outperform rating on the shares. The company delivered a “strong” Q3 with notable outperformance in its key segments, the analyst tells investors in a research note. The firm added that the Q3 results underscore a positive trajectory for Edwards, particularly with the momentum in transcatheter aortic valve replacements and potential catalysts from National Coverage Determination changes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $104 from $94 at Goldman Sachs
- Edwards Lifesciences price target raised to $95 from $89 at RBC Capital
- Edwards Lifesciences price target raised to $90 from $85 at JPMorgan
- Edwards Lifesciences price target raised to $83 from $81 at Baird
- Edwards Lifesciences price target raised to $100 from $90 at Mizuho